Why the study?
COVID-19 is frequently associated with endothelial dysfunction, but the relationship between acute disease severity and endothelial function in the early post-COVID-19 period was not well characterized.
Does greater acute COVID-19 disease severity correlate with higher odds of impaired endothelium-dependent vasodilation in the early post-COVID-19 period?
Cross-Sectional (n=529)
Does greater acute COVID-19 disease severity correlate with higher odds of impaired endothelium-dependent vasodilation in the early post-COVID-19 period?
Greater severity of acute COVID-19 is associated with a stepwise increase in the risk of functional and biochemical endothelial dysfunction during early recovery.
Answers are grounded in this paper and cite their sources.
Endothelial monitoring may be considered in severe survivors; hypothesis-generating and requires prospective validation.
COVID-19 is frequently associated with endothelial dysfunction, characterized by an imbalance between vasodilatory and vasoconstrictive mediators. This study evaluated endothelial function in the early post-COVID-19 period across groups of acute disease severity using flow-mediated dilation (FMD), circulating vasoactive biomarkers, and echocardiography. Serum endothelin-1 (ET-1), arginase-1 (Arg1), thromboxane A₂ (TxA₂)-related immunoreactivity, and prostacyclin (PGI₂)-related immunoreactivity were measured by enzyme-linked immunosorbent assay. An impaired FMD response was defined as < 10% brachial artery dilation from baseline. Overall, 502 post-COVID-19 patients were classified by acute COVID-19 severity as mild (n = 262), moderate (n = 183), severe (n = 41), or critical (n = 16); 27 healthy individuals served as a reference group. Impaired FMD responses were more frequent after severe (90.24%) and critical (100.00%) disease than in the reference group (18.52%). Greater acute disease severity was associated with progressively lower FMD values, smaller absolute brachial artery diameter changes, higher ET-1, Arg1, and TxA₂-related immunoreactivity, and lower PGI₂-related immunoreactivity. After adjustment for age, sex, body mass index, systolic blood pressure, smoking, diabetes mellitus, pre-existing cardiovascular disease, and post-COVID-19 interval, acute disease severity remained associated with impaired FMD (adjusted odds ratio 3.32, 95% confidence interval 2.29–4.82; p < 0.001 per one-category increase). Biomarker–FMD correlations were generally weak. Among patients assessed during the early post-COVID-19 period, greater acute COVID-19 severity was associated with greater impairment of endothelium-dependent vasodilation and an altered profile of circulating vasoactive biomarkers. These findings indicate associated functional and biochemical vascular abnormalities without establishing causality or a mechanistic relationship. Prospective longitudinal studies are needed to clarify their temporal evolution and clinical significance.
No takes yet. Share an insight, caveat, or question.
Palii et al. (2026) conducted a cross-sectional in post-COVID-19 (n=529). Acute COVID-19 disease severity vs. Healthy individuals or lower disease severity was evaluated on Impaired flow-mediated dilation (FMD) response (<10% brachial artery dilation) (adjusted OR 3.32, 95% CI 2.29–4.82, p=<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: